The Role of Testosterone Therapy in the Setting of Prostate Cancer

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2018 Jul 2

PMID 29961247

Citations 10

Authors

Katherine M Rodriguez

Alexander W Pastuszak

Mohit Khera

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The role of testosterone in the development of prostate cancer and the safety of testosterone therapy (TTh) after prostate cancer treatment, or in the setting of active surveillance, remains controversial. There are many concerns about using TTh in men, particularly those with a history of prostate cancer, ranging from a possible increased risk of cardiovascular disease to cancer progression or recurrence. With many prostate cancer patients living longer, and hypogonadism having significant morbidity, much care must go into the decision to treat. Here, we review the literature investigating the effects of testosterone on the prostate as well as the efficacy and safety of exogenous testosterone in men with a history of prostate cancer.

Recent Findings: The improvement in quality of life with TTh is well studied and understood, while the argument for significantly increased risk of cancer or other adverse effects is much less robust. Neither increased rates of prostate cancer, cancer recurrence, or cardiovascular risk have been well established. In men with high-risk prostate cancer, evidence in the setting of TTh is very limited, and TTh should be used with caution. The fears of TTh causing or worsening prostate cancer do not appear to be well supported by available data. Though more studies are needed to definitively determine the safety of TTh in men with prostate cancer, consideration should be given to treatment of hypogonadal men with a history of CaP.

Citing Articles

Effect of metabolic syndrome on testosterone levels in patients with metastatic prostate cancer: a real-world retrospective study.

Zhuo T, Yao X, Mei Y, Yang H, Maimaitiyiming A, Huang X PeerJ. 2024; 12:e17823.

PMID: 39099654 PMC: 11298165. DOI: 10.7717/peerj.17823.

Long-Term Exposure to Supraphysiological Levels of Testosterone Impacts Rat Submandibular Gland Proteome.

Valente-Santos J, Vitorino R, Sousa-Mendes C, Oliveira P, Colaco B, Faustino-Rocha A Int J Mol Sci. 2024; 25(1).

PMID: 38203721 PMC: 10778877. DOI: 10.3390/ijms25010550.

Molecular Mechanisms of Coffee on Prostate Cancer Prevention.

Montenegro J, Freitas-Silva O, Teodoro A Biomed Res Int. 2022; 2022:3254420.

PMID: 35496060 PMC: 9054433. DOI: 10.1155/2022/3254420.

Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient.

Bell D, Jerkins T Diabetes Ther. 2022; 13(5):1115-1119.

PMID: 35391594 PMC: 9076779. DOI: 10.1007/s13300-022-01256-6.

Identifying the outcomes important to men with hypogonadism: A qualitative evidence synthesis.

Aceves-Martins M, Quinton R, Brazzelli M, Cruickshank M, Manson P, Hudson J Andrology. 2022; 10(4):625-641.

PMID: 35064779 PMC: 9487983. DOI: 10.1111/andr.13156.

References

Corona G, Isidori A, Buvat J, Aversa A, Rastrelli G, Hackett G . Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014; 11(6):1577-92. DOI: 10.1111/jsm.12536. View

Porcaro A, Petroziello A, Brunelli M, De Luyk N, Cacciamani G, Corsi P . High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy. Urol Int. 2016; 96(4):470-8. DOI: 10.1159/000443742. View

Roder M, Christensen I, Berg K, Gruschy L, Brasso K, Iversen P . Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int. 2011; 109(4):520-4. DOI: 10.1111/j.1464-410X.2011.10335.x. View

Garcia-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M . Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int. 2012; 110(11 Pt B):E541-6. DOI: 10.1111/j.1464-410X.2012.11232.x. View

Calof O, Singh A, Lee M, Kenny A, Urban R, Tenover J . Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005; 60(11):1451-7. DOI: 10.1093/gerona/60.11.1451. View

Klap J, Schmid M, Loughlin K . The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol. 2014; 193(2):403-13. DOI: 10.1016/j.juro.2014.07.123. View

Loeb S, Folkvaljon Y, Damber J, Alukal J, Lambe M, Stattin P . Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. J Clin Oncol. 2017; 35(13):1430-1436. PMC: 5455459. DOI: 10.1200/JCO.2016.69.5304. View

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 167(2 Pt 2):948-51; discussion 952. View

Khera M, Bhattacharya R, Blick G, Kushner H, Nguyen D, Miner M . Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011; 186(3):1005-11. DOI: 10.1016/j.juro.2011.04.065. View

10.

Albuquerque G, Guglielmetti G, Barbosa J, Pontes Jr J, Fazoli A, Cordeiro M . Low serum testosterone is a predictor of high-grade disease in patients with prostate cancer. Rev Assoc Med Bras (1992). 2017; 63(8):704-710. DOI: 10.1590/1806-9282.63.08.704. View

11.

Baillargeon J, Urban R, Ottenbacher K, Pierson K, Goodwin J . Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013; 173(15):1465-6. PMC: 4100547. DOI: 10.1001/jamainternmed.2013.6895. View

12.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

13.

Soto A, Sonnenschein C . The two faces of janus: sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst. 2001; 93(22):1673-5. DOI: 10.1093/jnci/93.22.1673. View

14.

Morgentaler A, Bruning 3rd C, DeWolf W . Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996; 276(23):1904-6. View

15.

Araujo A, Esche G, Kupelian V, ODonnell A, Travison T, Williams R . Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007; 92(11):4241-7. DOI: 10.1210/jc.2007-1245. View

16.

Geck P, Maffini M, Szelei J, Sonnenschein C, Soto A . Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. Proc Natl Acad Sci U S A. 2000; 97(18):10185-90. PMC: 27796. DOI: 10.1073/pnas.97.18.10185. View

17.

Sarosdy M . Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2006; 109(3):536-41. DOI: 10.1002/cncr.22438. View

18.

Pastuszak A, Gomez L, Scovell J, Khera M, Lamb D, Lipshultz L . Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sex Med. 2015; 3(3):165-73. PMC: 4599554. DOI: 10.1002/sm2.76. View

19.

Morris M, Huang D, Kelly W, Slovin S, Stephenson R, Eicher C . Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009; 56(2):237-44. PMC: 2738932. DOI: 10.1016/j.eururo.2009.03.073. View

20.

Cunningham G, Hirshkowitz M, Korenman S, Karacan I . Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990; 70(3):792-7. DOI: 10.1210/jcem-70-3-792. View